Altium Capital

Altium Capital

Altium Capital was established in 2017 by Jacob Gottlieb in New York. Gottlieb previously built Visium Asset Management from a spinout of Balyasny Asset Management into an $8 billion platform before launching the current firm. The office manages private wealth through alternative investments with a primary emphasis on healthcare. The firm deploys capital into therapeutics via direct co-investments, SPVs, hedge fund strategies, and private equity structures. It covers early-stage, seed, pre-seed, and growth opportunities. Confirmed holdings include Antios Therapeutics, Cerevel Therapeutics, Chemomab Therapeutics, eGenesis, Gemini Therapeutics, Hummingbird Bioscience, Hyperfine, Immunovant, Ocuphire Pharma, Palisade Bio, Quoin Pharmaceuticals, Sagimet Biosciences, Seelos Therapeutics, Sonnet BioTherapeutics, Timber Pharmaceuticals, Vincerx Pharma, and Yumanity Therapeutics. Co-investors have included Abingworth, Bain Capital Life Sciences, OrbiMed, Novo Holdings, Frazier Healthcare Partners, and Sio Capital Management. Activity centers on North America with additional exposure through cross-border financings. Team size remains undisclosed. The firm lists one headquarters office in New York. Philanthropic vehicles include Altium Cares along with grants to the East Harlem Tutorial Program, New Yorkers for Children, Niskanen Center, Robin Hood Foundation, and The Windward School. No dated operational events from the last 24 months appear in available records. Altium Capital maintains a hybrid posture that combines single-family office capital with external co-investment syndicates. This structure allows the firm to lead or participate in PIPEs and venture rounds while sharing risk with other healthcare specialists such as Ikarian Capital and 683 Capital.